Cidara Therapeutics Inc (CDTX)
Official siteBIOTECHNOLOGY
Last updated: Jan 07, 2026 at 4:00 PM ET
Cidara Therapeutics Inc (CDTX) Financials: Revenue, Profit and Cash Flow
Cidara Therapeutics reported revenue of $1.27M for the fiscal year ended Dec 31, 2024, down 94.5% from the year before. That year, net income was -$169.83M with a net margin of -13319.8%, operating cash flow was -$176.53M and free cash flow was -$176.66M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$83.23M.
Revenue and Margins
Over the 5 years to Dec 2024, revenue fell from $20.91M, a compound annual decline of 42.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $1.27M | -94.5% | 100.0% | -13811.9% | -13319.8% |
| Dec 2023 | $23.28M | -63.9% | 100.0% | -116.2% | -98.5% |
| Dec 2022 | $64.45M | +30.0% | 100.0% | -52.0% | -52.1% |
| Dec 2021 | $49.57M | +310.8% | 100.0% | -85.2% | -85.7% |
| Dec 2020 | $12.07M | -42.3% | 100.0% | -595.4% | -597.6% |
| Dec 2019 | $20.91M | N/A | 100.0% | -199.5% | -196.5% |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
| Dec 2015 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27M | $23.28M | $64.45M | $49.57M | $12.07M | $20.91M | $0 | $0 | $0 | $0 |
| Gross profit | $1.27M | $23.28M | $64.45M | $49.57M | $12.07M | $20.91M | $0 | $0 | $0 | $0 |
| Research and development | $156.76M | $36.76M | $77.41M | $73.09M | $68.02M | $46.40M | $49.14M | $42.82M | $35.70M | $23.48M |
| Operating income | -$176.10M | -$27.06M | -$33.50M | -$42.26M | -$71.85M | -$41.72M | -$63.28M | -$55.72M | -$48.44M | -$32.31M |
| Net income | -$169.83M | -$22.93M | -$33.58M | -$42.47M | -$72.11M | -$41.09M | -$59.02M | -$55.73M | -$48.16M | -$32.19M |
| EBITDA | -$175.69M | -$26.86M | -$33.17M | N/A | -$70.79M | -$40.98M | -$59.08M | -$55.04M | -$47.88M | -$31.87M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$7.49M | $0 | $302.00K | $973.00K | -$17.13M | $9.22M | $5.09M | $26.11M | $10.38M |
| Gross profit | $0 | $0 | $0 | -$7.49M | $0 | $302.00K | $973.00K | -$17.13M | $9.22M | $5.09M | $26.11M | $10.38M |
| Operating income | -$88.63M | -$27.38M | -$25.27M | -$52.03M | -$17.39M | -$95.98M | -$8.54M | -$18.63M | -$4.47M | -$6.75M | $2.78M | -$17.05M |
| Net income | -$83.23M | -$25.72M | -$23.48M | -$52.31M | -$15.98M | -$91.21M | -$10.33M | -$3.21M | -$9.11M | -$13.62M | $3.01M | -$17.16M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of $1.64M by $188.18M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $214.80M | $67.03M | $47.49M | $75.33M | $60.42M | $68.98M | $79.11M | $79.03M | $106.96M | $109.97M |
| Current assets | $210.74M | $60.85M | $45.09M | $71.70M | $57.19M | $65.81M | $77.13M | $77.67M | $105.40M | $108.22M |
| Cash and equivalents | $189.82M | $35.78M | $32.73M | $59.68M | $35.91M | $50.27M | $74.56M | $60.81M | $85.37M | $62.56M |
| Total liabilities | $51.49M | $75.24M | $61.92M | $53.75M | $49.71M | $31.14M | $19.97M | $19.29M | $18.78M | $6.06M |
| Short-term debt | $1.64M | $1.30M | $1.21M | $2.59M | $7.02M | $9.96M | $9.93M | $2.67M | $0 | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $7.21M | $9.79M | $0 |
| Shareholder equity | $163.31M | -$8.21M | -$14.44M | $21.57M | $10.71M | $37.84M | $59.14M | $59.74M | $88.18M | $103.91M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $518.65M | $534.33M | $191.73M | $214.80M | $162.33M | $173.36M | $52.72M | $67.03M | $63.47M | $67.99M | $81.74M | $47.49M |
| Total liabilities | $96.26M | $33.15M | $50.05M | $51.49M | $46.70M | $42.42M | $70.50M | $75.24M | $55.43M | $52.57M | $54.90M | $61.92M |
| Cash and equivalents | $293.65M | $510.57M | $168.15M | $189.82M | $127.39M | $164.37M | $29.02M | $35.78M | $48.67M | $50.43M | $47.98M | $32.73M |
| Shareholder equity | $422.39M | $501.17M | $141.68M | $163.31M | $115.63M | $130.94M | -$17.78M | -$8.21M | $8.04M | $15.41M | $26.84M | -$14.44M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$176.53M | -$22.43M | -$28.47M | -$25.23M | -$54.41M | -$28.53M | -$56.70M | -$49.91M | -$39.77M | -$25.96M |
| Capital expenditures | $129.00K | $505.00K | $118.00K | $41.00K | $186.00K | $35.00K | $177.00K | $306.00K | $401.00K | $1.17M |
| Free cash flow | -$176.66M | -$22.94M | -$28.59M | -$25.27M | -$54.60M | -$28.57M | -$56.88M | -$50.22M | -$40.17M | -$27.13M |
| Share repurchases | N/A | N/A | $720.00K | $0 | $0 | $31.00K | $0 | $79.00K | $0 | $0 |
| Investing cash flow | -$129.00K | -$505.00K | -$118.00K | -$41.00K | -$186.00K | -$35.00K | $14.30M | $4.47M | $25.48M | -$46.09M |
| Financing cash flow | $337.06M | $25.98M | -$951.00K | $44.60M | $37.28M | $14.27M | $56.15M | $20.88M | $37.09M | $111.81M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.62M | -$40.96M | -$21.95M | -$29.41M | -$36.70M | -$103.78M | -$6.64M | -$12.72M | -$1.63M | $2.82M | -$10.90M | -$21.00M |
| Capital expenditures | $0 | $0 | $0 | $0 | $106.00K | $0 | $23.00K | $178.00K | $126.00K | $107.00K | $94.00K | $9.00K |
| Free cash flow | -$40.62M | -$40.96M | -$21.95M | -$29.41M | -$36.80M | -$103.78M | -$6.67M | -$12.90M | -$1.76M | $2.71M | -$10.99M | -$21.01M |
Frequently Asked Questions About CDTX
What is Cidara Therapeutics' annual revenue?
Cidara Therapeutics reported revenue of $1.27M for the fiscal year ended Dec 31, 2024.
How fast is Cidara Therapeutics' revenue growing?
Revenue was down 94.5% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -70.5%.
Is Cidara Therapeutics profitable?
No. Cidara Therapeutics reported net income of -$169.83M for the fiscal year ended Dec 31, 2024, with a net margin of -13319.8%.
How much free cash flow does CDTX generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$176.53M minus capital expenditures of $129.00K produced free cash flow of -$176.66M.
How much debt does Cidara Therapeutics have?
The balance sheet dated Dec 31, 2024 reported short-term debt of $1.64M and cash and equivalents of $189.82M.
CDTX pages: Overview, Financials